Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.
NASHVILLE, TN
Loading...
Price History
Market Data
| Market Cap | 2.68M |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | - |
| Current Ratio | 1.27 |
| Currency | USD |
Key Financial Metrics
4.05M
Revenue
-50.22M
Net Income
-
EPS (Diluted)
-44.33M
Free Cash Flow
Profitability
Gross Margin
57.0%
Operating Margin
-1260.8%
Net Profit Margin
-1238.5%
EBITDA
-48.93M
Returns & Efficiency
Return on Assets (ROA)
-195.0%
Return on Equity (ROE)
-
Dividend Yield
-
EPS
-
Financial Health
Total Assets
25.76M
Total Debt
-
Debt to Equity
-
Current Ratio
1.27
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | NASHVILLE, TN |
| Fiscal Year | 2025 |
Peers
44.92B
P/E: --
9.05B
P/E: --
VENAXIS, INC.
RIOT
9.05B
P/E: --
BIOPTIX, INC.
RIOT
9.05B
P/E: --
9.05B
P/E: --
5.94B
P/E: 28.0
ARCA BIOPHARMA, INC.
ORKA
3.76B
P/E: --
3.76B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$2.68M
P/E Ratio (TTM)-
Price to Book-
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin57.0%
Operating Margin-1260.8%
Net Margin-1238.5%
ROE-
ROA-195.0%
Leverage & Liquidity
Debt to Equity-
Current Ratio1.27
Total Debt-
Total Assets$25.76M
Stockholders' Equity$-31.46M
Income Statement (FY 2025)
Revenue$4.05M
Gross Profit$2.31M
Operating Income$-51.12M
Net Income$-50.22M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-44.33M
Cash & Equivalents$11.58M
Revenue Growth115.6%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 2 INTERNATIONAL PLAZA DR., SUITE 510 NASHVILLE, TN 37217 |
| Phone | N/A |
| Incorporated | CA, US |
| EIN | 271041563 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 536,000.00 |
| Stockholders' Equity | $-31.46M |
| Cash & Equivalents | $11.58M |
Recent Filings
View All
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-30
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-30
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-30
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-30
Local
SCHEDULE 13D/A
Amended Schedule 13D
Amendment to Schedule 13D
Filed: 2026-04-27
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-27
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-20
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-30
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-30
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-03-30
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-26
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-26
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-26
Local
SCHEDULE 13D/A
Amended Schedule 13D
Amendment to Schedule 13D
Filed: 2026-02-12
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-02-12
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | Insight Molecular Diagnostics Inc. |
| Ticker | IMDX |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | NASHVILLE, TN |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 2.68M |
| Revenue | 4.05M |
| Net Income | -50.22M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | -1238.5% |
| ROE | - |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...